Published May 10, 2019 | Version v1
Dataset Open

CRISPR knockout of EZH1 in AML cell line

Creators

  • 1. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network
  • 2. University Health Network
  • 3. Structural Genomics Consortium, University of Toronto
  • 4. Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • 5. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto

Description

We wanted to ensure the specificity of the EZH1 antibody that I was working with in previous posts, as well as creating a useful reagent to use in future experiments by generating a CRISPR knockout line of EZH1.

Notes

The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. This project receives funding from the Leukemia and Lymphoma Society of Canada.

Files

5-6-19 EZH1 Crispr knockout AML.pdf

Files (583.2 kB)

Name Size Download all
md5:d8b31545c1bc052ceeddc5b2bd862d76
236.9 kB Download
md5:dc6eb4c3631598e36618daf7908beeb5
346.4 kB Preview Download